Psyence Biomedical Ltd (PBM) Return on Equity ROE from the second quarter 2025 to second quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Psyence Biomedical ltd   (NASDAQ: PBM)

Psyence Biomedical Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Psyence Biomedical Ltd in the second quarter 2025?
Psyence Biomedical Ltd recorded a cumulative net loss of $-52 million during 12 months ending in the second quarter 2025, resulting in a negative return on equity (ROE) of -1110.39%.

Within the Major Pharmaceutical Preparations industry 30 other companies had a higher return on equity. While the total ranking for ROE unchanged, relative to the fourth quarter 2024 at no. .

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
II. Quarter		 (Mar 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -52 -51 -1 -1 -1
Return On Equity (TTM) -1110.39 % -3691.91 % - - -
PBM's Total Ranking # # # # #
Equity (TTM) in Millions 12 7 0 0 -1
Seq. Equity Change 76.54 % 2475 % - - -
Seq. Net Income Change - - - - -

Back to PBM Management Effectiveness >> PBM's 5 Years Annual ROE >> Compare PBM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 31
Sector # 87
Overall #

Return On Equity Statistics
High Average Low
15.05 %
-512.82 %
-1551.46 %
(Mar 31 2025)   (Jan 31 2022)





PBM Annual Return On Equity (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Jan 31 2023)
2023		 (Jan 31 2022)
2022		 (Jan 31 2021)
2021
Total Equity in Millions 7 -11 0 2 24
Y / Y Equity Change - - - -92.94 % -1.33 %
Net Income in Millions 1 -51 -3 -26 0
Y / Y Net Income Change - - - - -
Return On Equity 15.05 % - - -1551.46 % -2.05 %

Back to PBM Management Effectiveness >> PBM's 5 Years Annual ROE >> Compare PBM ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 15.05 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PBM's' Return on Equity at Yahoo Finance
PBM's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PBM's Competitors
Subscribers only: Roe for Psyence Biomedical Ltd 's Suppliers
Subscribers only: Return On Equity for PBM's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-07-07T12:30:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.